Published in Cornea on November 01, 2001
Animal models of bacterial keratitis. J Biomed Biotechnol (2011) 0.93
Colonization kinetics of different methicillin-resistant Staphylococcus aureus sequence types in pigs and host susceptibilities. Appl Environ Microbiol (2011) 0.87
Mixed human immunodeficiency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction. J Infect Dis (1988) 2.56
Resection of lung cancer invading the diaphragm. J Thorac Cardiovasc Surg (2000) 1.70
Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection. Infect Immun (1997) 1.69
Corneal virulence of Staphylococcus aureus: roles of alpha-toxin and protein A in pathogenesis. Infect Immun (1994) 1.45
Stages in phage R17 infection. VI. Injection of A protein and RNA into the host cell. Virology (1972) 1.45
The role of pneumolysin in ocular infections with Streptococcus pneumoniae. Curr Eye Res (1990) 1.23
Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit. Curr Eye Res (2001) 1.17
Cloning, expression, and affinity purification of recombinant Shigella flexneri invasion plasmid antigens IpaB and IpaC. Protein Expr Purif (1996) 1.15
Protease IV, a unique extracellular protease and virulence factor from Pseudomonas aeruginosa. J Biol Chem (1998) 1.14
Pseudomonas aeruginosa protease IV enzyme assays and comparison to other Pseudomonas proteases. Anal Biochem (2001) 1.13
Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci (1992) 1.11
Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci (2000) 1.10
Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res (1995) 1.08
Unusual arsenate poisoning of the F pili of Escherichia coli. J Bacteriol (1973) 1.07
Human antibody to influenza C virus: its age-related distribution and distinction from receptor analogs. Infect Immun (1980) 1.06
Pharmacokinetic considerations in the treatment of bacterial keratitis. Clin Pharmacokinet (1994) 1.04
Properties of influenza C virus grown in cell culture. J Virol (1977) 1.00
Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol (2002) 0.98
A radio frequency electric current enhances antibiotic efficacy against bacterial biofilms. Antimicrob Agents Chemother (2004) 0.97
Stress-associated immunomodulation and herpes simplex virus infections. Med Hypotheses (2001) 0.96
Pseudomonas aeruginosa protease IV produces corneal damage and contributes to bacterial virulence. Invest Ophthalmol Vis Sci (1998) 0.96
Nuclear exclusion of p53 in a subset of tumors requires MDM2 function. Oncogene (2000) 0.96
Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis. Infect Immun (2000) 0.95
Post traumatic tracheobronchial lesions. A follow-up study of 47 cases. Eur J Cardiothorac Surg (1991) 0.95
Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. Invest Ophthalmol Vis Sci (1994) 0.95
Identification of a novel 0.7-kb polyadenylated transcript in the LAT promoter region of HSV-1 that is strain specific and may contribute to virulence. Virology (1999) 0.95
Analysis of increasing antibiotic resistance of Klebsiella pneumoniae relative to changes in chemotherapy. J Infect Dis (1978) 0.95
Pseudomonas deficient in protease IV has significantly reduced corneal virulence. Invest Ophthalmol Vis Sci (1997) 0.94
Detection of influenza C virus by using an in situ esterase assay. J Clin Microbiol (1989) 0.93
Klebsiella neonatal injections: mechanism of broadening aminoglycoside resistance. Antimicrob Agents Chemother (1980) 0.93
Growth and virulence of a complement-activation-negative mutant of Streptococcus pneumoniae in the rabbit cornea. Curr Eye Res (1995) 0.93
Nerve growth factor antibody stimulates reactivation of ocular herpes simplex virus type 1 in latently infected rabbits. J Neurovirol (1997) 0.92
Effects of 100 mT time varying magnetic fields on the growth of tumors in mice. Bioelectromagnetics (2000) 0.92
Surfactant protein D in Pseudomonas aeruginosa keratitis. Ocul Immunol Inflamm (2007) 0.92
Staphylococcus corneal virulence in a new topical model of infection. Invest Ophthalmol Vis Sci (2001) 0.91
Extended wear contact lens usage induces Langerhans cell migration into cornea. Exp Eye Res (1999) 0.91
Identical 371-base-pair deletion mutations in the LAT genes of herpes simplex virus type 1 McKrae and 17syn+ result in different in vivo reactivation phenotypes. J Virol (1999) 0.91
Confirmation of the role of pneumolysin in ocular infections with Streptococcus pneumoniae. Curr Eye Res (1992) 0.91
Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin and cefazolin. Curr Eye Res (1992) 0.90
Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res (1993) 0.90
Pseudomonas aeruginosa keratitis in leukopenic rabbits. Curr Eye Res (1993) 0.89
Age and therapeutic outcome of experimental Pseudomonas aeruginosa keratitis treated with ciprofloxacin, prednisolone, and flurbiprofen. Antimicrob Agents Chemother (1993) 0.88
The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis. Cornea (1991) 0.88
Protein-protein interactions in the assembly of Shigella flexneri invasion plasmid antigens IpaB and IpaC into protein complexes. Biochim Biophys Acta (1998) 0.87
Successful treatment of methicillin-resistant Staphylococcus aureus Keratitis with topical ciprofloxacin. Ophthalmology (1991) 0.87
Histopathological studies of staphylococcal alpha-toxin: effects on rabbit corneas. Curr Eye Res (1997) 0.87
Systemic administration of leptin potentiates the response of neurons in the nucleus of the solitary tract to chemoreceptor activation in the rat. Neuroscience (2012) 0.86
Increasing bacterial resistance in pediatric acute conjunctivitis (1997-1998). Antimicrob Agents Chemother (2000) 0.86
HSV-1 migration in latently infected and naive rabbits after penetrating keratoplasty. Invest Ophthalmol Vis Sci (1999) 0.85
Iontophoresis of tobramycin for the treatment of experimental Pseudomonas keratitis in the rabbit. Arch Ophthalmol (1988) 0.85
Phospholipase A(2) in rabbit tears: a host defense against Staphylococcus aureus. Invest Ophthalmol Vis Sci (2001) 0.84
Physical stability and biological and physicochemical properties of twelve Pseudomonas aeruginosa bacteriophages. Virology (1969) 0.84
The growth of circumferential scars of the major airways from infancy to adulthood. Eur J Cardiothorac Surg (1990) 0.84
Serratia marcescens keratitis: strain-specific corneal pathogenesis in rabbits. Curr Eye Res (1999) 0.83
Ciprofloxacin and prednisolone therapy for experimental Pseudomonas keratitis. Curr Eye Res (1992) 0.82
Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits. Antimicrob Agents Chemother (2001) 0.81
Pseudomonas aeruginosa LasA protease and corneal infections. Curr Eye Res (2001) 0.81
Acute inflammation of the eyelid and cornea in Staphylococcus keratitis in the rabbit. Invest Ophthalmol Vis Sci (1999) 0.81
Ciprofloxacin iontophoresis for aminoglycoside-resistant pseudomonal keratitis. Invest Ophthalmol Vis Sci (1990) 0.81
First detection of resistance to QoI fungicides in Mycosphaerella graminicola on winter wheat in Belgium. Commun Agric Appl Biol Sci (2003) 0.80
Bioassays for quantitating ciprofloxacin and tobramycin in aqueous humor. J Ocul Pharmacol (1993) 0.79
Induction of chick embryo feather malformations by an influenza C virus. Teratology (1985) 0.79
Corneal virulence of LasA protease--deficient Pseudomonas aeruginosa PAO1. Cornea (2001) 0.79
Quinolones in collagen shields to treat aminoglycoside-resistant pseudomonal keratitis. Invest Ophthalmol Vis Sci (1990) 0.79
The effectiveness of tobramycin and Ocuflox in a prophylaxis model of Staphylococcus keratitis. Curr Eye Res (2001) 0.79
Clarithromycin for experimental Staphylococcus aureus keratitis. Curr Eye Res (1999) 0.79
No effect of short-term exposure to GSM-modulated low-power microwaves on benzo(a)pyrene-induced tumours in rat. Int J Radiat Biol (1999) 0.78
Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. Cornea (1993) 0.78
Antibody responses of mice exposed to low-power microwaves under combined, pulse-and-amplitude modulation. Bioelectromagnetics (1991) 0.77
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo. Curr Eye Res (2006) 0.77
Spore traps network: a new tool for predicting epidemics of wheat yellow rust. Commun Agric Appl Biol Sci (2011) 0.77
Keratotomy model of pseudomonas keratitis: gentamicin chemotherapy. Refract Corneal Surg (1992) 0.77
Effectiveness of Alpha-toxin Fab Monoclonal Antibody Therapy in Limiting the Pathology of Staphylococcus aureus Keratitis. Ocul Immunol Inflamm (2014) 0.77
Collagen shields containing tobramycin for sustained therapy (24 hours) of experimental Pseudomonas keratitis. CLAO J (1992) 0.76
Efficacy of tobramycin drops applied to collagen shields for experimental staphylococcal keratitis. Curr Eye Res (1994) 0.76
Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. Curr Eye Res (1998) 0.76
The effect of influenza C virus on the Purkinje cells of chick embryo cerebellum. Int J Dev Neurosci (1994) 0.76
U-56,407, a new antibiotic related to asukamycin: isolation and characterization. J Antibiot (Tokyo) (1983) 0.76
Chick embryo brain cultures enriched for neurons or astroglial cells support the replication of influenza A, B, and C viruses. In Vitro Cell Dev Biol Anim (1997) 0.76
The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. Jpn J Ophthalmol (1996) 0.76
Microbial formation of 4-thiouracil. Antimicrob Agents Chemother (1977) 0.76